February 25, 2022

Phase Ib/IIa Clinical Trial of AD17002-AI for House Dust Mite-Induced Allergic Rhinitis Completes Testing and 8-Week Hospital Follow-up for All Subjects in Cohort 2 (Mid-Dose Group).